Govt to come with plans to improve bulk drug mfg capacities

Image
Press Trust of India New Delhi
Last Updated : Feb 18 2015 | 1:20 PM IST
The government will shortly come out with strategies to improve bulk drug manufacturing capacity in India in order to reduce dependence on China for import of bulk drugs.
"We are importing 70-80 per cent bulk drugs from China. We will shortly come out with strategies to improve our bulk drug capacity in India.
There was a time when India was producing bulk drugs in a big way and now nothing," Pharmaceuticals Secretary V K Subburaj said at an event organised by industry body Assocham.
He said the committee set up by the government has submitted its recommendations and the Department of Pharmaceuticals is examining it and will come out with its strategies shortly.
These strategies will be part of the proposed bulk drug pharma policy.
In order to help bulk drugs manufacturing in India, the government is also working on a revival package for Hindustan Antibiotics Ltd (HAL).
"Right now, HAL is not producing anything. They have working capital problems. But they have big 270 acres land in Pune. We have worked out a revival package for HAL which will go to the cabinet very shortly," Subburaj said.
The Maharashtra-based HAL was the first drug manufacturing unit in the country to commercially produce antibiotics.
Subburaj said the government will also look at reviving Indian Drugs and Pharmaceuticals Ltd (IDPL).
The government is in discussion with state governments including Telangana, Andhra Pradesh, Rajasthan and Madhya Pradesh to create bulk drug capacities.
"In 10 years time, our bulk drug dependence on China should reduce significantly. Concern is dependence on a single source," he added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 18 2015 | 1:20 PM IST

Next Story